Mylan ($MYL) has let authorities in India know that if they approve its planned $1.6 billion deal to buy Strides Arcolab's sterile injectables unit, Agila Specialties, it intends to more than triple the sterile injectable production aimed at the Indian market. The plans are outlined in a filing with India's Department of Industrial Policy and Promotion (DIPP), which has delayed approval of the deal over concerns that Mylan might slight the domestic market once the deal is complete. Story | More